Alto Neuroscience posts $244.2M cash estimate, plans ALTO-207 trial
Alto Neuroscience, Inc. reported a preliminary estimate of its cash, cash equivalents and restricted cash of approximately $244.2 million as of June 30, 2026.
Rhea-AI Filing Summary
Alto Neuroscience, Inc. reported a preliminary estimate of its cash, cash equivalents and restricted cash of approximately $244.2 million as of June 30, 2026. This figure is based on management’s estimates, has not been audited, reviewed or compiled by the independent registered public accounting firm, and may change after completion of accounting procedures for the quarter ended June 30, 2026; any differences may be material.
The company also outlined a pipeline update, stating that it intends to accelerate and expand clinical development of its ALTO-207 program, including conducting an additional planned Phase 3 trial of ALTO-207 as monotherapy for treatment-resistant depression.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 2.02, 8.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Cash, cash equivalents and restricted cash: $244.2 million
Form type: Form 8-K
Phase of new ALTO-207 trial: Phase 3
3 metrics
Cash, cash equivalents and restricted cash
$244.2 million
Preliminary estimate as of June 30, 2026
Form type
Form 8-K
Current report filed under the Securities Exchange Act of 1934
Phase of new ALTO-207 trial
Phase 3
Planned additional monotherapy trial for treatment-resistant depression
Key Terms
restricted cash, treatment-resistant depression, Phase 3 trial, forward-looking statements, +1 more
5 terms
restricted cash financial
"it estimates that its cash, cash equivalents and restricted cash were approximately"
Cash that a company holds but cannot use for day-to-day operations because it is set aside for a specific purpose—such as meeting loan covenants, serving as collateral, funding an escrow, or complying with regulations. Like money in a locked savings account earmarked for a bill, restricted cash reduces the cash available to run the business and pay dividends or debts, so investors treat it differently when assessing a company’s true short-term financial strength.
treatment-resistant depression medical
"Phase 3 trial of ALTO-207 as monotherapy for the treatment of treatment-resistant depression"
A form of major depression that does not improve after a person has tried standard treatments such as common antidepressant medications and therapy; think of it as a stubborn problem that doesn’t respond to the usual fixes. It matters to investors because it represents a large unmet medical need and a higher-risk, higher-reward area for drug developers, with potential for premium pricing, regulatory scrutiny, and durable demand if an effective new therapy is approved.
Phase 3 trial medical
"conduct an additional planned Phase 3 trial of ALTO-207 as monotherapy"
A Phase 3 trial is a large, late-stage test of a new drug or medical treatment done on many people to make sure it really works and is safe. For investors, it matters because a successful Phase 3 usually means the company can ask regulators to sell the product and could earn lots of money, while failure can sharply reduce the company’s value.
forward-looking statements regulatory
"contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
emerging growth company regulatory
"Emerging growth company x"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What cash balance did Alto Neuroscience (ANRO) estimate as of June 30, 2026?
Alto Neuroscience estimated cash, cash equivalents and restricted cash of approximately $244.2 million as of June 30, 2026. This amount is preliminary, unaudited, and may change after full quarter-end accounting procedures are completed.
Is Alto Neuroscience’s $244.2 million cash figure for ANRO audited?
No. The $244.2 million cash, cash equivalents and restricted cash estimate has not been audited, reviewed, or compiled by Alto Neuroscience’s independent registered public accounting firm and may differ materially once full accounting is completed.
What pipeline update did Alto Neuroscience (ANRO) provide for ALTO-207?
Alto Neuroscience stated it intends to accelerate and expand clinical development of ALTO-207, including an additional planned Phase 3 trial of ALTO-207 as monotherapy for the treatment of treatment-resistant depression.
What indication is Alto Neuroscience’s ALTO-207 program targeting according to this 8-K?
The ALTO-207 program is being developed for treatment-resistant depression. Alto Neuroscience plans an additional Phase 3 monotherapy trial to further evaluate ALTO-207 in this patient population.
Does Alto Neuroscience (ANRO) commit to updating its forward-looking statements about ALTO-207?
Alto Neuroscience states that its forward-looking statements speak only as of the date of the report and it disclaims any obligation to update them, except as may be required by law.
AI-generated analysis. How Rhea-AI works. Not financial advice.
